Aldosterone action in the heart

Pflugers Archiv European Journal of Physiology

Volumn 446, Issue 3, 2003, Pages 328-333

  Firsov, Dmitri ^a   Muller, Olivier G ^a  

^a University of Lausanne Departement de Pharmacologie et de Toxicologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID RECEPTOR; PLACEBO; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONFERENCE PAPER; HEART; HEART FAILURE; HEART VENTRICLE REMODELING; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SODIUM LOAD; SODIUM TRANSPORT; VASCULAR FIBROSIS;

EID: 0038726482     PISSN: 00316768     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00424-003-1049-4     Document Type: Conference Paper

References (79)

1. Andren B, Lind L, Hedenstierna G, Lithell H (1996) Left ventricular hypertrophy and geometry in a population sample of elderly males. Eur Heart J 17:1800-1807
2. Kuroda T, Shiina A, Tsuruda K, Fujita T, Yamasawa M, Mitsuhashi T, Suzuki O, Yaginuma T, Hosoda S (1989) Mass screening of cardiovascular disorders by two-dimensional echocardiography. J Cardiol 19:933-943
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1989) Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham heart study. Ann Intern Med 110:101-107
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322:1561-1566
5. Luscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434-2440
6. Orth SR, Viedt C, Amann K, Ritz E (2001) Endothelin in renal diseases and cardiovascular remodeling in renal failure. Intern Med 40:285-291
7. Vecchione C, Fratta L, Rizzoni D, Notre A, Poulet R, Ported E, Frati G, Guelfi D, Trimarco V, Mulvany MJ, Agabiti-Rosei E, Trimarco B, Cotecchia S, Lembo G (2002) Cardiovascular influences of alphalb-adrenergic receptor defect in mice. Circulation 105:1700-1707
8. Regan CP, Anderson PG, Bishop SP, Berecek KH (1997) Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats. Am J Physiol 272:H2131-2138
9. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ (1998) Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 98:2765-2773
10. Peng H, Carretero OA, Alfie ME, Masura JA, Rhaleb NE (2001) Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. Hypertension 37:974-980
11. Madeddu P, Emanueli C, Maestri R, Salis MB, Minasi A, Capogrossi MC, Olivetti G (2000) Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice. Hypertension 35:391-396
12. Karam H, Heudes D, Gonzales MF, Loffler BM, Clozel M, Clozel JP (1996) Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. Am J Hypertens 9:991-998
13. Raman VK, Lee YA, Lindpaintner K (1995) The cardiac reninangiotensin-aldosterone system and hypertensive cardiac hypertrophy (review, 44 references). Am J Cardiol 76:18D-23D
14. Ngarmukos C, Grekin RJ (2001) Nontraditional aspects of aldosterone physiology. Am J Physiol 281:E1122-1127
15. Young MJ, Funder JW (2002) Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens 20:1465-1468
16. Okubo S, Niimura F, Nishimura H, Takemoto F, Fogo A, Matsusaka T, Ichikawa I (1997) Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 99:855-860
17. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C (1998) Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273:4883-4891
18. Delcayre C, Silvestre JS (1999) Aldosterone and the heart: towards a physiological function? Cardiovasc Res 43:7-12
19. Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, Robert V (2000) Cardiac aldosterone production and ventricular remodeling. Kidney Int 57:1346-1351
20. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H (2000) Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 141:1901-1904
21. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H (2000) Cardiac aldosterone production in genetically hypertensive rats. Hypertension 36:495-500
22. Wu P, Guo Z, Zhang Y, Liu Y, Liang X, Zhang R, Lai W, Takeda Y, Isamu M, Takeda R (1998) Aldosterone overproduction and CYP11B2 mRNA overexpression in vessels of spontaneously hypertensive rats. Horm Res 50:28-31
23. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K (2001) Aldosterone production is activated in failing ventricle in humans. Circulation 103:72-77
24. Mizuno Y, Yasue H, Yoshimura M, Fujii H, Yamamoto N, Nakayama M, Harada E, Sakamoto T, Nakamura S, Ito T, Shimasaki Y, Ogawa H, Saito Y, Nakao K (2002) Effects of perindopril on aldosterone production in the failing human heart. Am J Cardiol 89:1197-1200
25. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y, Sakamoto T, Yamamuro M, Saito Y, Nakao K, Yasue H, Ogawa H (2002) Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 87:3936-3940
26. MacKenzie SM, Clark CJ, Fraser R, Gomez-Sanchez CE, Connell JM, Davies E (2000) Expression of 11 beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol 24:321-328
27. MacKenzie SM, Clark CJ, Ingram MC, Lai M, Seckl J, Gomez-Sanchez CE, Fraser R, Connell JM, Davies E (2000) Corticosteroid production by fetal rat hippocampal neurons. Endocr Res 26:531-535
28. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP (1997) Aldosterone biosynthesis in the rat brain. Endocrinology 138:3369-3373
29. Satoh M, Nakamura M, Saitoh H, Satoh H, Akatsu T, Iwasaka J, Masuda T, Hiramori K (2002) Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 102:381-386
30. Slight SH, Joseph J, Ganjam VK, Weber KT (1999) Extraadrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol 31:1175-1184
31. Young MJ, Clyne CD, Cole TJ, Funder JW (2001) Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 86:5121-5126
32. Farman N (1999) Molecular and cellular determinants of mineralocorticoid selectivity. Curr Opin Nephrol Hypertens 8:45-51
33. Funder JW (2001) Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens 10:227-230
34. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
35. Beggar AT, Escoubet B, Puttini S, Cailmail S, Delage V, Ouvrard-Pascaud A, Bocchi B, Peuchmaur M, Delcayre C, Farman N, Jaisser F (2002) Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA 99:7160-7165
36. Escoubet B, Coureau C, Blot-Chabaud M, Bonvalet JP, Farman N (1996) Corticosteroid receptor mRNA expression is unaffected by corticosteroids in rat kidney, heart, and colon. Am J Physiol 270:C1343-1353
37. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P (1996) Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 33:315-326
38. Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, Seckl JR (1996) The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology 137:794-797
39. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP (1995) Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 92:175-182
40. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71:503-510
41. Kayes-Wandover KM, White PC (2000) Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 85:2519-2525
42. Romero DG, Zhou M, Gomez-Sanchez CE (2000) Cloning and expression of the bovine 11beta-hydroxysteroid dehydrogenase type-2. J Steroid Biochem Mol Biol 72:231-237
43. Smith RE, Little PJ, Maguire JA, Stein-Oakley AN, Krozowski ZS (1996) Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin Exp Pharmacol Physiol 23:549-551
44. Condon J, Ricketts ML, Whorwood CB, Stewart PM (1997) Ontogeny and sexual dimorphic expression of mouse type 2 11beta-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 127:121-128
45. Roland BL, Funder JW (1996) Localization of 11beta-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies. Endocrinology 137:1123-1128
46. Sheppard KE, Autelitano DJ (2002) 11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 143:198-204
47. Trapp T, Rupprecht R, Castren M, Reul JM, Holsboer F (1994) Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron 13:1457-62
48. Trapp T, Holsboer F (1996) Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trends Pharmacol Sci 17:145-149
49. Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP (1998) A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol 274: C1245-1252
50. Stier CT Jr, Chander PN, Rocha R (2002) Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10:97-107
51. Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893-901
52. Brilla CG, Matsubara LS, Weber KT (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A-16A
53. Brilla CG, Matsubara LS, Weber KT (1993) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25:563-575
54. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C (1994) Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 24:30-36
55. Young M, Fullerton M, Dilley R, Funder J (1994) Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93:2578-2583
56. Young M, Head G, Funder J (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269:E657-662
57. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:457-465
58. Rocha R, Chander PN, Zuckerman A, Stier CT Jr (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33:232-237
59. Benetos A, Lacolley P, Safar ME (1997) Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17:1152-1156
60. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC (2001) Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37:787-793
61. (+)-ATPase gene expression in adult and neonatal rat cardiocytes. J Biol Chem 266:12058-12066
62. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C (1995) Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26:971-978
63. 2+ exchanger in aldosterone/salt-induced hypertension in guinea pigs. Cardiovasc Res 38:451-462
64. Korichneva I, Puceat M, Millanvoye-Van Brussel E, Geraud G, Vassort G (1995) Aldosterone modulates both the Na/H antiport and Cl/HCO3 exchanger in cultured neonatal rat cardiac cells. J Mol Cell Cardiol 27:2521-2528
65. (+) pump. Circ Res 86:37-42
66. (2+) current in adult rat cardiomyocytes. Circ Res 85:1139-1145
67. + current density in rat ventricular myocytes. J Physiol (Lond) 537:151-160
68. 2+ current in neonatal mice. Circ Res 85:168-173
69. Ouvrard-Pascaud A, Jaisser F (2003) Pathophysiological role of the mineralocorticoid receptor in heart: analysis of conditional transgenic models. Pflugers Arch 445:477-481
70. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombes M (2001) Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 276:38911-38920
71. Qin W, Goellner JJ, Rocha R, Rudolph AE, Bond BR, Daust HA, Robinson EL, Ghosh S, McMahon EG (2002) 11b HSD2 over-expression in cardiomyocytes leads to severe dilated cardiac hypertrophy and fibrosis in transgenic mice (abstract). The Endocrine Society's 84th Annual Meeting
72. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709-717
73. Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 102:2700-2706
74. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC (2002) Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40:23-27
75. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC (1996) Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039-1045
76. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC (1997) Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95:1471-1478
77. Spindler B, Mastroberardino L, Custer M, Verrey F (1997) Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia, Pflugers Arch 434:323-331
78. Robert-Nicoud M, Flahaut M, Elalouf JM, Nicod M, Salinas M, Bens M, Doucet A, Wincker P, Artiguenave F, Horisberger JD, Vandewalle A, Rossier BC, Firsov D (2001) Transcriptome of a mouse kidney conical colecting duct cell line: effects of aldosterone and vasopressin. Proc Natl Acad Sci USA 98:2712-2716
79. Loffing J, Summa V, Zecevic M, Verrey F (2001) Mediators of aldosterone action in the renal tubule. Curr Opin Nephrol Hypertens 10:667-675